These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8768925)

  • 1. Treatment of anemia of nephrotic syndrome with recombinant erythropoietin.
    Gansevoort RT; Vaziri ND; de Jong PE
    Am J Kidney Dis; 1996 Aug; 28(2):274-7. PubMed ID: 8768925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Urinary erythropoietin excretion: an unknown cause of anemia during nephrotic syndrome].
    Terrier B; Fakhouri F; Sultanik P; Delarue R; Hummel A
    Rev Med Interne; 2006 Aug; 27(8):643-5. PubMed ID: 16876918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function.
    Feinstein S; Becker-Cohen R; Algur N; Raveh D; Shalev H; Shvil Y; Frishberg Y
    Am J Kidney Dis; 2001 Apr; 37(4):736-42. PubMed ID: 11273873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction.
    Ishimitsu T; Ono H; Sugiyama M; Asakawa H; Oka K; Numabe A; Abe M; Matsuoka H; Yagi S
    Nephron; 1996; 74(3):607-10. PubMed ID: 8938689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of anemia in patients with nephrotic syndrome.
    Shibasaki T; Misawa T; Matsumoto H; Abe S; Nakano H; Matsuda H; Gomi H; Ohno I; Ishimoto F; Sakai O
    Nihon Jinzo Gakkai Shi; 1994 Aug; 36(8):896-901. PubMed ID: 7933664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of human erythropoietin (hEPO) treatment on anemia in ICR-derived glomerulonephritis (ICGN) mice.
    Miyamoto Y; Kuramitsu-Miyamoto K; Iwanaga E; Uchio-Yamada K; Yamaguchi-Yamada M; Ogura A; Manabe N
    Exp Anim; 2005 Apr; 54(2):181-4. PubMed ID: 15897628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function.
    Stuart M
    Clin Pediatr (Phila); 2002 Jun; 41(5):361. PubMed ID: 12086203
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant EPO therapy increases erythrocyte expression of complement regulatory proteins.
    Ohi H; Tamano M; Sudo S; Okada N
    Am J Kidney Dis; 2003 Jan; 41(1):179-85. PubMed ID: 12500235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin.
    Bayés B; Serra A; Juncà J; Lauzurica R
    Nephrol Dial Transplant; 1998 Jul; 13(7):1894-5. PubMed ID: 9681764
    [No Abstract]   [Full Text] [Related]  

  • 10. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis.
    Takashina N; Kondo H; Kashiwazaki S
    J Rheumatol; 1990 Jul; 17(7):885-7. PubMed ID: 2213753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin and transferrin metabolism in nephrotic syndrome.
    Vaziri ND
    Am J Kidney Dis; 2001 Jul; 38(1):1-8. PubMed ID: 11431174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of daily subcutaneous administration of recombinant erythropoietin on chronic anemia in rheumatoid arthritis.
    Kato Y; Takagi C; Tanaka J; Masaki Y; Furuya H
    Intern Med; 1994 Apr; 33(4):193-7. PubMed ID: 8069012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis?
    Caillette A; Barreto S; Gimenez E; Labeeuw M; Zech P
    Clin Nephrol; 1993 Sep; 40(3):176-8. PubMed ID: 8403574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin use in CKD patients with cancer: to tread with caution?
    Nayak-Rao S; McCormick B
    J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
    Trkulja V
    Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia in nephrotic syndrome: approach to evaluation and treatment.
    Iorember F; Aviles D
    Pediatr Nephrol; 2017 Aug; 32(8):1323-1330. PubMed ID: 27999949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia and erythropoietin treatment in chronic kidney diseases.
    Santoro A; Canova C
    Minerva Urol Nefrol; 2005 Mar; 57(1):23-31. PubMed ID: 15944519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin safety and efficacy in chronic allograft nephropathy.
    Baltar J; Moran N; Ortega F; Ortega T; Rebollo P; Cofan F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2245-7. PubMed ID: 17889152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin: receptors and clinical use in rheumatoid arthritis.
    Krantz SB; Sawyer ST; Sawada K; Wolfe F; Bocagno J
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():181-95; discussion 195-8. PubMed ID: 2157776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.